Johns Hopkins Cancer Center | Strategic Alliance Partners

Latest from Johns Hopkins Cancer Center


Chemotherapy-Free Strategies Chart a New Course for Ph-Positive ALL

August 24, 2021

A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

Novel Compound Looks to Shake Up mCRPC Treatment Landscape

August 19, 2021

The discovery of an agent with a unique mechanism of action led investigators to examine sabizabulin, an oral therapy that binds to the colchicine binding site on the microtubule to crosslink α and β tubulin and inhibits microtubule polymerization.

Neoadjuvant Nivolumab/Chemo Improves pCR in Resectable NSCLC

April 10, 2021

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Systemic Treatment Options Expand in Nonmetastatic NSCLC

February 05, 2021

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

August 20, 2020

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.